Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma

Anil Potti, Apar Kishor Ganti, Kaley Sholes, Eric Langness, Vijay Koka, Linda Horvarth, Michael Koch

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the relationship, if any, between pesticide exposure and overexpression of the HER-2/neu oncoprotein in extensive stage small cell lung cancer (ESSCLC). Experimental Design: The records of all patients with a diagnosis of ESSCLC from January 1991 through April 2001 were reviewed in our retrospective study. Pesticide risk (herbicide and insecticide) was assessed by telephone interviews using a predetermined questionnaire with emphasis on type of exposure, use of protective measures, and duration of exposure. An exposure index was calculated (h/day × days/year × years), and patients with an index > 2400 h were considered as exposed. HER-2/neu overexpression was assessed by immunohistochemistry using the Hercep test developed by Dako. Statistical analysis was performed using SPSS-10. Results: A total of 193 patients (84 females and 109 males), with a mean age of 68.5 years (range, 42-90 years) were included in the study. Of these, 57 (29.5%) revealed HER-2/neu overexpression by immunohistochemistry. After adjusting for age, smoking, Eastern Cooperative Oncology Group score, and treatment, HER-2/neu overexpression was associated with a statistically significant diminished survival (P < 0.001; Mann-Whitney U test). We contacted 53 of 57 patients with overexpression and 121 of 136 patients without HER-2/neu overexpression to ascertain a history of pesticide exposure. Forty-one of 53 (77.4%) patients with HER-2/neu overexpression and 47 of the 121 patients without overexpression (38.8%) were exposed to pesticides. We found that patients with history of pesticide exposure had a higher risk of having HER-2/neu overexpression (odds ratio, 5. 38; P < 0.01, 95% confidence interval, 2.5-11.2) Conclusions: HER-2/neu is overexpressed in ∼30% patients with ESSCLC and is associated with decreased survival. Also, pesticide exposure seems to be related to HER2/neu overexpression seen in our patient population. Future studies are needed to validate our findings and also to determine which pesticide(s)/pesticide components are actually responsible for HER-2/neu overexpression seen in ESSCLC.

Original languageEnglish (US)
Pages (from-to)4872-4876
Number of pages5
JournalClinical Cancer Research
Volume9
Issue number13
StatePublished - Oct 15 2003

Fingerprint

Small Cell Lung Carcinoma
Pesticides
Immunohistochemistry
Survival
Oncogene Proteins
Herbicides
Nonparametric Statistics
Insecticides
Research Design
Retrospective Studies
Smoking
Odds Ratio
Confidence Intervals
Interviews

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma. / Potti, Anil; Ganti, Apar Kishor; Sholes, Kaley; Langness, Eric; Koka, Vijay; Horvarth, Linda; Koch, Michael.

In: Clinical Cancer Research, Vol. 9, No. 13, 15.10.2003, p. 4872-4876.

Research output: Contribution to journalArticle

Potti, A, Ganti, AK, Sholes, K, Langness, E, Koka, V, Horvarth, L & Koch, M 2003, 'Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma', Clinical Cancer Research, vol. 9, no. 13, pp. 4872-4876.
Potti, Anil ; Ganti, Apar Kishor ; Sholes, Kaley ; Langness, Eric ; Koka, Vijay ; Horvarth, Linda ; Koch, Michael. / Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 13. pp. 4872-4876.
@article{5a11041a4cf1457a84e1e03c8fbc6e08,
title = "Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma",
abstract = "Purpose: The aim of this study was to evaluate the relationship, if any, between pesticide exposure and overexpression of the HER-2/neu oncoprotein in extensive stage small cell lung cancer (ESSCLC). Experimental Design: The records of all patients with a diagnosis of ESSCLC from January 1991 through April 2001 were reviewed in our retrospective study. Pesticide risk (herbicide and insecticide) was assessed by telephone interviews using a predetermined questionnaire with emphasis on type of exposure, use of protective measures, and duration of exposure. An exposure index was calculated (h/day × days/year × years), and patients with an index > 2400 h were considered as exposed. HER-2/neu overexpression was assessed by immunohistochemistry using the Hercep test developed by Dako. Statistical analysis was performed using SPSS-10. Results: A total of 193 patients (84 females and 109 males), with a mean age of 68.5 years (range, 42-90 years) were included in the study. Of these, 57 (29.5{\%}) revealed HER-2/neu overexpression by immunohistochemistry. After adjusting for age, smoking, Eastern Cooperative Oncology Group score, and treatment, HER-2/neu overexpression was associated with a statistically significant diminished survival (P < 0.001; Mann-Whitney U test). We contacted 53 of 57 patients with overexpression and 121 of 136 patients without HER-2/neu overexpression to ascertain a history of pesticide exposure. Forty-one of 53 (77.4{\%}) patients with HER-2/neu overexpression and 47 of the 121 patients without overexpression (38.8{\%}) were exposed to pesticides. We found that patients with history of pesticide exposure had a higher risk of having HER-2/neu overexpression (odds ratio, 5. 38; P < 0.01, 95{\%} confidence interval, 2.5-11.2) Conclusions: HER-2/neu is overexpressed in ∼30{\%} patients with ESSCLC and is associated with decreased survival. Also, pesticide exposure seems to be related to HER2/neu overexpression seen in our patient population. Future studies are needed to validate our findings and also to determine which pesticide(s)/pesticide components are actually responsible for HER-2/neu overexpression seen in ESSCLC.",
author = "Anil Potti and Ganti, {Apar Kishor} and Kaley Sholes and Eric Langness and Vijay Koka and Linda Horvarth and Michael Koch",
year = "2003",
month = "10",
day = "15",
language = "English (US)",
volume = "9",
pages = "4872--4876",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma

AU - Potti, Anil

AU - Ganti, Apar Kishor

AU - Sholes, Kaley

AU - Langness, Eric

AU - Koka, Vijay

AU - Horvarth, Linda

AU - Koch, Michael

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Purpose: The aim of this study was to evaluate the relationship, if any, between pesticide exposure and overexpression of the HER-2/neu oncoprotein in extensive stage small cell lung cancer (ESSCLC). Experimental Design: The records of all patients with a diagnosis of ESSCLC from January 1991 through April 2001 were reviewed in our retrospective study. Pesticide risk (herbicide and insecticide) was assessed by telephone interviews using a predetermined questionnaire with emphasis on type of exposure, use of protective measures, and duration of exposure. An exposure index was calculated (h/day × days/year × years), and patients with an index > 2400 h were considered as exposed. HER-2/neu overexpression was assessed by immunohistochemistry using the Hercep test developed by Dako. Statistical analysis was performed using SPSS-10. Results: A total of 193 patients (84 females and 109 males), with a mean age of 68.5 years (range, 42-90 years) were included in the study. Of these, 57 (29.5%) revealed HER-2/neu overexpression by immunohistochemistry. After adjusting for age, smoking, Eastern Cooperative Oncology Group score, and treatment, HER-2/neu overexpression was associated with a statistically significant diminished survival (P < 0.001; Mann-Whitney U test). We contacted 53 of 57 patients with overexpression and 121 of 136 patients without HER-2/neu overexpression to ascertain a history of pesticide exposure. Forty-one of 53 (77.4%) patients with HER-2/neu overexpression and 47 of the 121 patients without overexpression (38.8%) were exposed to pesticides. We found that patients with history of pesticide exposure had a higher risk of having HER-2/neu overexpression (odds ratio, 5. 38; P < 0.01, 95% confidence interval, 2.5-11.2) Conclusions: HER-2/neu is overexpressed in ∼30% patients with ESSCLC and is associated with decreased survival. Also, pesticide exposure seems to be related to HER2/neu overexpression seen in our patient population. Future studies are needed to validate our findings and also to determine which pesticide(s)/pesticide components are actually responsible for HER-2/neu overexpression seen in ESSCLC.

AB - Purpose: The aim of this study was to evaluate the relationship, if any, between pesticide exposure and overexpression of the HER-2/neu oncoprotein in extensive stage small cell lung cancer (ESSCLC). Experimental Design: The records of all patients with a diagnosis of ESSCLC from January 1991 through April 2001 were reviewed in our retrospective study. Pesticide risk (herbicide and insecticide) was assessed by telephone interviews using a predetermined questionnaire with emphasis on type of exposure, use of protective measures, and duration of exposure. An exposure index was calculated (h/day × days/year × years), and patients with an index > 2400 h were considered as exposed. HER-2/neu overexpression was assessed by immunohistochemistry using the Hercep test developed by Dako. Statistical analysis was performed using SPSS-10. Results: A total of 193 patients (84 females and 109 males), with a mean age of 68.5 years (range, 42-90 years) were included in the study. Of these, 57 (29.5%) revealed HER-2/neu overexpression by immunohistochemistry. After adjusting for age, smoking, Eastern Cooperative Oncology Group score, and treatment, HER-2/neu overexpression was associated with a statistically significant diminished survival (P < 0.001; Mann-Whitney U test). We contacted 53 of 57 patients with overexpression and 121 of 136 patients without HER-2/neu overexpression to ascertain a history of pesticide exposure. Forty-one of 53 (77.4%) patients with HER-2/neu overexpression and 47 of the 121 patients without overexpression (38.8%) were exposed to pesticides. We found that patients with history of pesticide exposure had a higher risk of having HER-2/neu overexpression (odds ratio, 5. 38; P < 0.01, 95% confidence interval, 2.5-11.2) Conclusions: HER-2/neu is overexpressed in ∼30% patients with ESSCLC and is associated with decreased survival. Also, pesticide exposure seems to be related to HER2/neu overexpression seen in our patient population. Future studies are needed to validate our findings and also to determine which pesticide(s)/pesticide components are actually responsible for HER-2/neu overexpression seen in ESSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0142219326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142219326&partnerID=8YFLogxK

M3 - Article

C2 - 14581360

AN - SCOPUS:0142219326

VL - 9

SP - 4872

EP - 4876

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -